The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patient...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2019-06, Vol.153 (3), p.562-567
Main Authors: van Baal, J.O.A.M., Van de Vijver, K.K., Algera, M.D., van der Aa, M.A., Sonke, G.S., van Driel, W.J., Kenter, G.G., Amant, F.C., Lok, C.A.R.
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Early stage ovarian cancer
High-grade serous ovarian cancer
Staging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713
cites cdi_FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713
container_end_page 567
container_issue 3
container_start_page 562
container_title Gynecologic oncology
container_volume 153
creator van Baal, J.O.A.M.
Van de Vijver, K.K.
Algera, M.D.
van der Aa, M.A.
Sonke, G.S.
van Driel, W.J.
Kenter, G.G.
Amant, F.C.
Lok, C.A.R.
description The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22–0.64; p 
doi_str_mv 10.1016/j.ygyno.2019.03.257
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2204695581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825819304925</els_id><sourcerecordid>2204695581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCL0BCPnJJGH8k6xw4oIqWlSr1Us6W44w3Xu3Gi-0E7b-vly09chpp9My8Mw8hnxjUDFj7dVeftqcp1BxYV4OoebN-Q1YMuqZqVdO9JSuADirFG3VFrlPaAYAAxt-TKwGdVKwTKzI9jUjRObSZBkfNsJsXM2VqRzyEPGI0xxMNE01zXPxi9tRP9Giyxykn-sfnkd5t7h9pymaLdENHvx2rbTQD0oQxzImGxURvJmrNZDF-IO-c2Sf8-FJvyK-7H0-3P6uHx_vN7feHykqQuZJt56RrB2alUlyonjHmOraWfHDgZC-k5QYMmtJmTnWwVqbv-6YdpERcM3FDvlz2HmP4PWPK-uCTxf3eTFiu0pxDyWgadUbFBbUxpBTR6WP0BxNPmoE-i9Y7_Ve0PovWIHQRXaY-vwTM_QGH15l_Zgvw7QJgeXPxGHWyxZrFwcciWw_B_zfgGdfkkPo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2204695581</pqid></control><display><type>article</type><title>The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer</title><source>ScienceDirect Freedom Collection</source><creator>van Baal, J.O.A.M. ; Van de Vijver, K.K. ; Algera, M.D. ; van der Aa, M.A. ; Sonke, G.S. ; van Driel, W.J. ; Kenter, G.G. ; Amant, F.C. ; Lok, C.A.R.</creator><creatorcontrib>van Baal, J.O.A.M. ; Van de Vijver, K.K. ; Algera, M.D. ; van der Aa, M.A. ; Sonke, G.S. ; van Driel, W.J. ; Kenter, G.G. ; Amant, F.C. ; Lok, C.A.R.</creatorcontrib><description>The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22–0.64; p &lt; 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28–0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging. •Until now, no consensus has been reached on the benefit of adjuvant chemotherapy for early stage HGSOC.•After optimal staging and FIGO stage I HGSOC, adjuvant chemotherapy favors long-term RFS and OS.•Chemotherapy should be considered after optimal staging for FIGO stage I HGSOC to improve RFS and OS.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2019.03.257</identifier><identifier>PMID: 30948193</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant chemotherapy ; Early stage ovarian cancer ; High-grade serous ovarian cancer ; Staging</subject><ispartof>Gynecologic oncology, 2019-06, Vol.153 (3), p.562-567</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713</citedby><cites>FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30948193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Baal, J.O.A.M.</creatorcontrib><creatorcontrib>Van de Vijver, K.K.</creatorcontrib><creatorcontrib>Algera, M.D.</creatorcontrib><creatorcontrib>van der Aa, M.A.</creatorcontrib><creatorcontrib>Sonke, G.S.</creatorcontrib><creatorcontrib>van Driel, W.J.</creatorcontrib><creatorcontrib>Kenter, G.G.</creatorcontrib><creatorcontrib>Amant, F.C.</creatorcontrib><creatorcontrib>Lok, C.A.R.</creatorcontrib><title>The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22–0.64; p &lt; 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28–0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging. •Until now, no consensus has been reached on the benefit of adjuvant chemotherapy for early stage HGSOC.•After optimal staging and FIGO stage I HGSOC, adjuvant chemotherapy favors long-term RFS and OS.•Chemotherapy should be considered after optimal staging for FIGO stage I HGSOC to improve RFS and OS.</description><subject>Adjuvant chemotherapy</subject><subject>Early stage ovarian cancer</subject><subject>High-grade serous ovarian cancer</subject><subject>Staging</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi0EotvCL0BCPnJJGH8k6xw4oIqWlSr1Us6W44w3Xu3Gi-0E7b-vly09chpp9My8Mw8hnxjUDFj7dVeftqcp1BxYV4OoebN-Q1YMuqZqVdO9JSuADirFG3VFrlPaAYAAxt-TKwGdVKwTKzI9jUjRObSZBkfNsJsXM2VqRzyEPGI0xxMNE01zXPxi9tRP9Giyxykn-sfnkd5t7h9pymaLdENHvx2rbTQD0oQxzImGxURvJmrNZDF-IO-c2Sf8-FJvyK-7H0-3P6uHx_vN7feHykqQuZJt56RrB2alUlyonjHmOraWfHDgZC-k5QYMmtJmTnWwVqbv-6YdpERcM3FDvlz2HmP4PWPK-uCTxf3eTFiu0pxDyWgadUbFBbUxpBTR6WP0BxNPmoE-i9Y7_Ve0PovWIHQRXaY-vwTM_QGH15l_Zgvw7QJgeXPxGHWyxZrFwcciWw_B_zfgGdfkkPo</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>van Baal, J.O.A.M.</creator><creator>Van de Vijver, K.K.</creator><creator>Algera, M.D.</creator><creator>van der Aa, M.A.</creator><creator>Sonke, G.S.</creator><creator>van Driel, W.J.</creator><creator>Kenter, G.G.</creator><creator>Amant, F.C.</creator><creator>Lok, C.A.R.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201906</creationdate><title>The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer</title><author>van Baal, J.O.A.M. ; Van de Vijver, K.K. ; Algera, M.D. ; van der Aa, M.A. ; Sonke, G.S. ; van Driel, W.J. ; Kenter, G.G. ; Amant, F.C. ; Lok, C.A.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adjuvant chemotherapy</topic><topic>Early stage ovarian cancer</topic><topic>High-grade serous ovarian cancer</topic><topic>Staging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Baal, J.O.A.M.</creatorcontrib><creatorcontrib>Van de Vijver, K.K.</creatorcontrib><creatorcontrib>Algera, M.D.</creatorcontrib><creatorcontrib>van der Aa, M.A.</creatorcontrib><creatorcontrib>Sonke, G.S.</creatorcontrib><creatorcontrib>van Driel, W.J.</creatorcontrib><creatorcontrib>Kenter, G.G.</creatorcontrib><creatorcontrib>Amant, F.C.</creatorcontrib><creatorcontrib>Lok, C.A.R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Baal, J.O.A.M.</au><au>Van de Vijver, K.K.</au><au>Algera, M.D.</au><au>van der Aa, M.A.</au><au>Sonke, G.S.</au><au>van Driel, W.J.</au><au>Kenter, G.G.</au><au>Amant, F.C.</au><au>Lok, C.A.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>153</volume><issue>3</issue><spage>562</spage><epage>567</epage><pages>562-567</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22–0.64; p &lt; 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28–0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging. •Until now, no consensus has been reached on the benefit of adjuvant chemotherapy for early stage HGSOC.•After optimal staging and FIGO stage I HGSOC, adjuvant chemotherapy favors long-term RFS and OS.•Chemotherapy should be considered after optimal staging for FIGO stage I HGSOC to improve RFS and OS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30948193</pmid><doi>10.1016/j.ygyno.2019.03.257</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2019-06, Vol.153 (3), p.562-567
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_2204695581
source ScienceDirect Freedom Collection
subjects Adjuvant chemotherapy
Early stage ovarian cancer
High-grade serous ovarian cancer
Staging
title The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A21%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20adjuvant%20chemotherapy%20on%20survival%20in%20patients%20with%20FIGO%20stage%20I%20high-grade%20serous%20ovarian%20cancer&rft.jtitle=Gynecologic%20oncology&rft.au=van%20Baal,%20J.O.A.M.&rft.date=2019-06&rft.volume=153&rft.issue=3&rft.spage=562&rft.epage=567&rft.pages=562-567&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2019.03.257&rft_dat=%3Cproquest_cross%3E2204695581%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-469f4f6d1c488238b111f91742df0f4b34c2a0aea11f1f89078abbb56d44ee713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2204695581&rft_id=info:pmid/30948193&rfr_iscdi=true